Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


There's More To Patient Experience Data Submissions Than Just Guidances, Advocates Tell US FDA

Executive Summary

Forthcoming 'guidance on guidance,' required under 21st Century Cures Act, should explain different ways that advocacy groups can get patient experience data in front of FDA and provide an opportunity for early interactions before groups go down the guidance development route.

Related Content

Patient Experience Data: US FDA Guidance Offers Other Ways To Share
US FDA Mulling Core Criteria For Patient-Reported Outcomes
Disease-Specific Guidances Reflect US FDA's 'Nimble, Collaborative, Patient-Focused' Approach
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program
FDA's 21st Century Cures Plan Gives Patient-Focused Drug Development A Boost





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts